Prediction of benefit from adjuvant treatment in patients with breast cancer

Clinical Breast Cancer

Volumn 10, Issue SUPPL. 1, 2010, Pages

  Eng Wong, Jennifer ^a   Isaacs, Claudine ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Gene signature; Intrinsic subtype; Molecular profiling; Recurrence risk

Indexed keywords

BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC PROCEDURES; HUMAN; MAMMAPRINT; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PROGNOSIS; RECURRENCE SCORE; REVIEW;

EID: 77954449333     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.s.005     Document Type: Article

References (44)

1. Eifel P, Axelson JA, Costa J, et al. National Institutes Of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93:979-989
2. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009; 7:122-192
3. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated internationalexpert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21:3357-3365 (Pubitemid 46606270)
4. Fisher B, Jeong JH, Dignam J, et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001; 30:62-66
5. Dowsett M. The top ten research priorities in translational research in breast cancer [Web site]. Available at: http://www.toptenresearch.org. Accessed: May 2, 2010.
6. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20:1319-1329
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Clarke M, Coates AS, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: Patient-level meta-analysis of randomised trials. Lancet 2008; 371:29-40.
9. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19:980-991
10. Allred DC, Carlson RW, Berry DA, et al. NCCN task force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw 2009; 7(suppl 6):S1-S21; quiz S22-23.
11. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model adjuvant! For early breast cancer. J Clin Oncol 2005; 23:2716-2725
12. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817-2826
13. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8:R25.
14. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:3726-3734
15. Henry LR, Stojadinovic A, Swain SM, et al. The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 2009; 99:319-323
16. Oratz R, Paul D, Cohn A, et al. Impact of Oncotype DXTM on decision making in breast cancer clinical practice. Paper presented at: the 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. Abstract 2049.
17. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26:721-728
18. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008; 26:4063-4071
19. Albain K, Barlow W, O'Malley F, et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Paper presented at: the 27th Annual San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio, TX. Abstract 37.
20. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11:55-65.
21. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-6.
22. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009.
23. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98:1183-1192
24. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752
25. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-10874
26. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, her2 status, and prognosis of patients with luminal b breast cancer. J Natl Cancer Inst 2009; 101:736-750
27. Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer 2008; 123:236-240
28. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295:2492-2502
29. Ruiz-Borrego M, Moreno A, Salvador J, et al. Different treatment benefit for luminal A and luminal B advanced breast cancinomas receiving aromatase inhibitors. Cancer Res 2009; 69(24 suppl):812S (abstract 5141).
30. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13:2329-2334
31. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7:96.
32. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27:1160-1167
33. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005; 102:3738-3743
34. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004; 2:E7.
35. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365:671-679
36. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5:607-616
37. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355:560-569
38. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10:R65.
39. Simes RJ, Coates AS. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr 2001; 146-152
40. Cardoso F, van't Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008; 26:729-735
41. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86:97-100.
42. Trial using docetaxel cytoxan in breast cancers with high recurrence scores. ClinicalTrials.gov [Web site]. Available at: http://clinicaltrials.gov/ ct2/show/study/nct00832338. Accessed: May 4, 2010.
43. Exemestane or docetaxel-cytoxan in low recurrence score cancers. ClinicalTrials.gov [Web site]. Available at: http://clinicaltrials.gov/ct2/show/ study/nct00941330. Accessed: May 4, 2010.
44. Straehle C, Cardoso F, Azambuja E, et al. Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer. Crit Care Med 2009; 37:S22-9.